Targeted immunotherapy shows promise for tough prostate cancers

This study tested whether a combination of two immunotherapy drugs could help control advanced prostate cancer that had stopped responding to standard hormone treatments. The trial specifically enrolled 69 men whose cancers had certain genetic features that might make them more responsive to immunotherapy. Participants received the two-drug combination for four cycles, followed by one of the drugs alone for up to a year, while researchers monitored how well the treatment controlled the cancer.